A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the ...
Dec 7, 2015
0
73
(HealthDay)—Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who ...
Nov 30, 2015
0
1
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer. The process, developed ...
Nov 20, 2015
0
19
Pevonedistat is a first-in-class, investigational small-molecule inhibitor of the NEDD8-activating enzyme, explained Shah. "This enzyme is part of the ubiquitin-proteasome system, which is the target of a number of FDA-approved ...
Nov 11, 2015
0
22
Researchers in the West Midlands have made a breakthrough in explaining how an incurable type of blood cancer develops from an often symptomless prior blood disorder. The findings could lead to more effective treatments and ...
Oct 16, 2015
0
21
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer ...
Aug 26, 2015
0
51
Testing for genetic risk factors could improve treatment for myeloma - a cancer of the blood and bone marrow - by helping doctors identify patients at risk of developing more aggressive disease.
Aug 17, 2015
0
41
Genetic research is a key to understanding how either race or ethnicity affect the incidence of different cancers and how these factors may contribute to different responses to the same treatments. Multiple myeloma, a blood ...
Jul 15, 2015
0
20
Multiple myeloma uses a trick akin to a wolf in sheep's clothing to grow in and spread to new bone sites. By overexpressing Runx2, a gene that normally is a master regulator of bone formation, the cells of this largely incurable ...
Jul 10, 2015
0
40
(HealthDay)—A two-pronged immune-boosting drug could provide new hope for people stricken with multiple myeloma, a cancer of the blood and bone marrow, according to clinical trial findings.
Jun 2, 2015
0
20
